I am working on a Medscape article about new approaches to managing COPD and asthma that go beyond standard inhaler therapy. I am seeking U.S.-based pulmonologists or physicians with experience in pulmonary medicine to share insights on emerging strategies in clinical practice and research.
Questions:
What innovations in COPD and asthma care are you seeing beyond pharmacotherapy (e.g., breathing techniques, pulmonary rehab, personalized approaches)?
Are you using or researching personalized oxygen protocols? If so, how do they compare with standard oxygen therapy?
What role do biologic or precision-medicine therapies play in COPD and asthma management today?
What barriers exist in implementing these newer approaches (cost, access, adherence)?
How can primary care providers best incorporate or refer for these innovations?
Looking ahead, what developments are most promising for improving COPD and asthma outcomes over the next 5 years?
posted10/14/2025
deadline10/16/2025
processing
published
Recently published by Medscape
Cardio docs & PharmDs re: on beta blockers’ risk in women post MI
I’m seeking board-certified cardiologists, cardiovascular researchers, or pharmDs to comment on a recent study indicating that women treated with beta blockers after myocardial infarction have a higher risk of death, recurrent MI, or hospitalization for heart failure compared to men.
I’d like to hear from experts who can discuss:
Possible physiological or pharmacologic reasons for sex-based differences in beta blocker response
Whether this study challenges current post-MI management guidelines
How these findings could impact clinical decision-making for female patients